Advertisement

Zusammenfassung: immunologische Reaktionsabläufe bei malignen Erkrankungen

  • V. Schirrmacher
Conference paper

Zusammenfassung

Der vorliegende Beitrag behandelt neuere Erkenntnisse über Immunreaktion gegenüber Tumoren. Dieses schließt die Identifizierung neuer tumorassoziierte Antigene sowie die Regulation von Antitumorimmunreaktionen durch Zytokine, akzessorische Molekülen und Wachstumsfaktoren ein. TumorWirtsinteraktionen führen auch zur Generierung von Tumor-ImmunescapeVarianten, die ebenfalls diskutiert werden. Schließlich werden Ansätze zu Immun- und Gentherapien erläutert und es wird kurz auf einige Probleme bei der Durchführung klinischer Krebsimmuntherapiestudien eingegangen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altevogt P, Hoegen P von, Schirrmacher V (1986) Immunoresistant metastatic tumor variants can re-express their tumor antigen after treatment with DNA methylation-inhibiting agents. Int J Cancer 38: 707–711PubMedCrossRefGoogle Scholar
  2. Barnd Di, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Sci USA 86: 7159–7163CrossRefGoogle Scholar
  3. Bosslet K, Schirrmacher V (1982) High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line ( ESb ). Int J Cancer 29: 195–202PubMedCrossRefGoogle Scholar
  4. Chen L, Ashe S, Bradey WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of anti-tumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093–1102PubMedCrossRefGoogle Scholar
  5. Fearon E, Pardoll D, Itaya T et al. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 6o: 397–403CrossRefGoogle Scholar
  6. Foa R, Giovarelli M, Jemma C, Pierro MT, Lusso P, Ferrando ML, Lauria F and Forni G (1985) Interleukin-2 (II-2) and interferon-y production by T lymphocytes from patients with B-chronic lymphoytic leukemia: evidence that normally released II-2 is absorbed by the neoplastic B cell population. Blood 66: 2614–2619Google Scholar
  7. Gansbacher B, Zier K, Daniels B, Cronin K, Bannedi R, Gilboa E (1990 a) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217–1224Google Scholar
  8. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Giboa E (1990 b) Retroviral vector-mediated gamma interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50: 7820–7825Google Scholar
  9. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, Van der Eh AJ, Melief CJ (1989) Eradication of adenovirus E1-induced tumors by EiA-specific cytotoxic T lymphocytes. Cell 59: 603–614PubMedCrossRefGoogle Scholar
  10. Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Murphy AR, Takatsuki K (1989) Cytotoxicity of interleukin-2 toxin towards lymphocytes from patients with adult T cell leukemia. Cancer Res 49: 4042–4046PubMedGoogle Scholar
  11. Lassam N, Jay G (1989) Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. J Immunol 143: 3792–3797PubMedGoogle Scholar
  12. Lenschow DJ, Zeng Y, Thisthlewaite JR, Montag A, Brady W, Gibson ML, Linsley PS, Bluestone JA (1992) Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g. Science 257: 789–792PubMedCrossRefGoogle Scholar
  13. Lurquin C, Van Pel AL, Marianne B et al. (1989) Structure of the gene of tum-transplantation antigen P91 A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58: 293–303PubMedCrossRefGoogle Scholar
  14. Maki RG, Old LJ, Strivastava PK (1990) Human homologue of murine tumor rejection antigen gp 96: 5’ regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci USA 87: 5652–5658Google Scholar
  15. Messner HA (1991) Bone marrow transplantation in hemopoietic malignancies. Curr Op Oncol 3: 245–253CrossRefGoogle Scholar
  16. Mukerji B, Chakraborty NG, Sivanandham M (1990) T-cell clones that react against autologous human tumors. Immunol Rev 116: 33–62CrossRefGoogle Scholar
  17. Notter M, Schirrmacher V (1990) Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells. Int J Cancer 45: 834–841PubMedCrossRefGoogle Scholar
  18. Osband ME. Ross S (1990) Problems in the investigational study and clinical use of cancer immunotherapy. Immunol Today 11: 193–195Google Scholar
  19. Perdrizet GA, Ross SR, Stauss HJ, Singh S, Koeppen H, Schreiber H (1990) Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med 171: 1205–1220PubMedCrossRefGoogle Scholar
  20. Porgador A, Feldman M, Eisenbach L (1989) H-rKb transfection of Bi6 melanoma cells results in reduced tumorigenicity and metastatic competence. J Immunogenet 16: 291–303PubMedCrossRefGoogle Scholar
  21. Rosenberg SA, Schwarz SL, Spiess PJ (1988) Combination immunotherapy for cancer: synergistic anti tumor interactions of interleukin-2, alfa interferon and tumor-infiltrating lymphocytes. J Natl Cancer Inst 80: 1393–1397PubMedCrossRefGoogle Scholar
  22. Schirrmacher V (1990) Krebsimpfung mit Tumorzellen. Spektrum der Wissenschaft Januar: 38–50Google Scholar
  23. Schirrmacher V, Barz D (1986) Characterization of cellular and extracellular plasmamembrane vesicles from a low metastatic lymphoma (Eb) and its high metastatic variant (ESb): inhibitory capacity in cell-cell interaction systems. Biochem Biophys Acta 860: 236–242PubMedCrossRefGoogle Scholar
  24. Schirrmacher V, Jacobs W (1979) Tumor metastases and cell-mediated immunity in a model systems in DBA/2 mice. VIII. Expression and shedding of Fc gamma receptors on metastatic tumor cell variants. J Supramol Struct 11: 105–111PubMedCrossRefGoogle Scholar
  25. Schirrmacher V, Josimociv-Alasevic O, Osawa H, Diamantstein T (1987) Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of animals bearing II-2 receptor positive tumors with high or low metastatic capacity. Br J Cancer 55: 583–587PubMedCrossRefGoogle Scholar
  26. Sibille C, Chomez P, Wildmann C et al. (1990) Structure of the gene of tum-transplantation antigen p 198: a point-mutation generates a new antigenic peptide. J Exp Med 172: 35–45PubMedCrossRefGoogle Scholar
  27. Slavin S, Nagler A (1991) New developments in bone marrow transplantation. Curr Op Oncol 3: 254–271CrossRefGoogle Scholar
  28. Stevenson HC, Foon KA, Kanapa DJ, Favilla T, Beman I, Oldham RK (1984) The potential value of cytapheresis for adoptive immunotherapy of cancer patients. Plasma Ther Transfusion Technol 5: 237–250Google Scholar
  29. Stickney DR, Foon KA (1992) Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases. Current Opinion Onco 4: 847–855CrossRefGoogle Scholar
  30. Suto R, Srivastava PK (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585-1588PubMedCrossRefGoogle Scholar
  31. Szikora J, Van Pel A, Birchard V et al. (1990) Structure of the gene of turn-transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J 9: 104Google Scholar
  32. Tepper R, Pattengale P, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503–512PubMedCrossRefGoogle Scholar
  33. Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells. Science 259: 368–370PubMedCrossRefGoogle Scholar
  34. Turks LA, Linsley PS, LinH, Brady W, Leiden JM, Wei RQ, Gibson M, Zheng XG, Myrdal S, Gordon D et al. (1992) T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 89: 1110 2–1110 6Google Scholar
  35. Van der Bruggen P, Traversari C, Chomez P et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643PubMedCrossRefGoogle Scholar
  36. Versteeg, R, Kruse-Wolters KM, Plomp AC et al. (1989a) Suppression of class I human HLA by c-myc is locus specific. J Exp Med 170: 621–635PubMedCrossRefGoogle Scholar
  37. Versteeg R, Peltenberg L, Plomp AC, Schreier PI (1989 b) High expression of the c-myc oncogene renders melanoma cells prone to lysis by NK cells. J Immunol 143: 4331–4337Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • V. Schirrmacher

There are no affiliations available

Personalised recommendations